Alto Neuroscience Inc., a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, announced new data and analyses from its development programs at the 64th Annual Meeting of the American College of Neuropsychopharmacology (ACNP) held January 12-15, 2026. The presentations included findings on ALTO-203, an H3 inverse agonist, which was shown to improve sustained attention and wakefulness, particularly in individuals with abnormal theta/beta ratios. Additional data validated Theta-ITC as a robust EEG biomarker for detecting cognitive impairment associated with schizophrenia, based on a large independent patient sample. Alto also reported the development and validation of an EEG biomarker that predicts placebo response in major depressive disorder, with analyses indicating enhanced treatment effect detection when accounting for individual differences. All results were presented at the ACNP 2026 meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260113754206) on January 13, 2026, and is solely responsible for the information contained therein.